Medifoxamine
Medifoxamine
Medifoxamine (pronunciation: me-di-fox-a-mine) is a dopamine antagonist and serotonin antagonist that was formerly used as an antidepressant. It was developed in the 1970s by the French pharmaceutical company Laboratoires Dausse and was sold under the brand name Clédial.
Etymology
The term "Medifoxamine" is derived from the combination of the words "medicine" and "foxamine", where "foxamine" is a hypothetical compound. The exact etymology is not known as it is a proprietary name given by the manufacturing company.
Pharmacology
Medifoxamine acts by inhibiting the reuptake of dopamine and serotonin, two neurotransmitters that play a crucial role in mood regulation. By blocking their reuptake, medifoxamine increases the levels of these neurotransmitters in the brain, which can help to alleviate the symptoms of depression.
Related Terms
- Dopamine: A neurotransmitter that plays a major role in reward-motivated behavior. Most types of reward increase the level of dopamine in the brain.
- Serotonin: A neurotransmitter that contributes to feelings of well-being and happiness. It is also involved in the regulation of mood, appetite, and sleep.
- Antidepressant: A class of medications used to treat major depressive disorder and other mood disorders.
- Laboratoires Dausse: A French pharmaceutical company that developed medifoxamine.
See Also
External links
- Medical encyclopedia article on Medifoxamine
- Wikipedia's article - Medifoxamine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski